Immunohistochemical analysis revealed that FOSL1 staining intensity was markedly elevated in tumor cells from TMZ‐resistant GBM patients relative to those from TMZ‐sensitive patients (Figure 1E). This evidence concerns the gene FOSL1 and glioblastoma.